Coronary Artery Disease
Conditions
Brief summary
This study is designed to validate the hypothesis that the treatment of rosuvastatin could increase the score of Calcification of Coronary artery(CAC) density in coronary artery disease(CAD) patients with diabetes mellitus.CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.
Detailed description
Calcification of atherosclerotic plaque is a complicated and organic active process, which is one of the main pathologic features of atherosclerosis. Widely coverage of CAC is correlated with the greater likelihood of coronary events.With the increasing density of CAC, the risk of cardiovascular disease (CVD) declines.Some studies showed that the calcified plaque in stable CHD is denser. Statins are widely used in the treatment of atherosclerotic cardiovascular disease. Treatment of statins may increase the density score of CAC, thus, promote the unstable atherosclerotic plaque to the stable plaque.
Interventions
DRUGrosuvastatin
CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.
Sponsors
Sir Run Run Shaw Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Provision of informed consent prior to any study specific procedures 2. Male and female adults aged 18-70 years old 3. CHD patients without stent implantation determined by coronary angiography or coronary CT examination; 4. Combined with type 2 diabetes: HbA1c≥6.5%, FPG≥7.0mmol/L, 2h blood glucose≥11.1mmol/L 5. Patients who confirmed CAC(Agatston score ≥50,measured by 64 row spiral CT6)
Exclusion criteria
1. CHD Patients plan to recieve coronary stenting implantation or coronary artery bypass grafting; 2. Patients combined with severe pulmonary, liver and kidney dysfunction 3. Classed as III-IV grade of New York Heart Association functional 4. Pregnancy test was positive，lactation woman and in women of child-bearing potential not using appropriate contraceptive measures. 5. Life expectancy within 24 months or less 6. Patients combined valvular heart disease and cardiomyopathy 7. Patients combined cancer 8. Patients with atrial fibrillation 9. Patients who is allergic to statins 10. Patients with myopathy 11. Patients with active liver disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the Density Score of Coronary Artery Calcification in CAD patients with Diabetes Mellitus | 24 months |
Secondary
| Measure | Time frame |
|---|---|
| the level of serum sclerostin in CAD patients with diabetes mellitus | 24months |
| the volume score of CAC in CAD patients with diabetes mellitus | 24 months |
Contacts
Primary ContactGuosheng Fu, MD/PhD
Backup ContactWenbin Zhang
Outcome results
None listed